Ionis Pharmaceuticals Inc (IONS)
38.76
+0.37
(+0.96%)
USD |
NASDAQ |
Nov 01, 16:00
38.76
0.00 (0.00%)
After-Hours: 20:00
Ionis Pharmaceuticals Enterprise Value: 5.311B for Nov. 1, 2024
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| November 01, 2024 | 5.311B |
| October 31, 2024 | 5.253B |
| October 30, 2024 | 5.390B |
| October 29, 2024 | 5.461B |
| October 28, 2024 | 5.563B |
| October 25, 2024 | 5.379B |
| October 24, 2024 | 5.313B |
| October 23, 2024 | 5.257B |
| October 22, 2024 | 5.298B |
| October 21, 2024 | 5.349B |
| October 18, 2024 | 5.456B |
| October 17, 2024 | 5.268B |
| October 16, 2024 | 5.374B |
| October 15, 2024 | 5.166B |
| October 14, 2024 | 5.290B |
| October 11, 2024 | 5.261B |
| October 10, 2024 | 5.183B |
| October 09, 2024 | 5.201B |
| October 08, 2024 | 5.160B |
| October 07, 2024 | 5.169B |
| October 04, 2024 | 5.177B |
| October 03, 2024 | 5.161B |
| October 02, 2024 | 5.409B |
| October 01, 2024 | 5.360B |
| September 30, 2024 | 5.516B |
| Date | Value |
|---|---|
| September 27, 2024 | 5.641B |
| September 26, 2024 | 5.680B |
| September 25, 2024 | 5.663B |
| September 24, 2024 | 5.664B |
| September 23, 2024 | 5.795B |
| September 20, 2024 | 5.942B |
| September 19, 2024 | 5.939B |
| September 18, 2024 | 5.879B |
| September 17, 2024 | 5.745B |
| September 16, 2024 | 5.617B |
| September 13, 2024 | 5.852B |
| September 12, 2024 | 5.667B |
| September 11, 2024 | 5.906B |
| September 10, 2024 | 5.396B |
| September 09, 2024 | 6.264B |
| September 06, 2024 | 6.054B |
| September 05, 2024 | 6.238B |
| September 04, 2024 | 6.165B |
| September 03, 2024 | 6.115B |
| August 30, 2024 | 6.169B |
| August 29, 2024 | 6.494B |
| August 28, 2024 | 6.399B |
| August 27, 2024 | 6.267B |
| August 26, 2024 | 6.041B |
| August 23, 2024 | 6.058B |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
2.911B
Minimum
Dec 01 2021
7.969B
Maximum
Jan 25 2021
5.313B
Average
5.213B
Median
Aug 26 2022
Enterprise Value Benchmarks
| Biogen Inc | 29.92B |
| Alnylam Pharmaceuticals Inc | 33.57B |
| Biomarin Pharmaceutical Inc | 12.36B |
| Rigel Pharmaceuticals Inc | 260.44M |
| Apellis Pharmaceuticals Inc | 3.504B |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -66.26M |
| Revenue (Quarterly) | 225.25M |
| Total Expenses (Quarterly) | 291.34M |
| EPS Diluted (Quarterly) | -0.45 |
| Gross Profit Margin (Quarterly) | 98.15% |
| Profit Margin (Quarterly) | -29.42% |
| Earnings Yield | -6.50% |
| Normalized Earnings Yield | -7.883 |